In response to media reports, Hong Kong pharmacies sell Pfizer and Meridodong two crown disease oral drugs. The Hong Kong Department of Health said that the pharmacy selling crown disease oral drugs to citizens is illegal and officials will strengthen inspections.

The Hong Kong Special Administrative Region Government issued a newsletter on Friday (December 30) stating that Pfizer Hong Kong Co., Ltd. and the United States Mosha Dong Pharmaceutical Co., Ltd. supplied to Hong Kong's crown disease oral drugs, PAXLOVID and Monpiravir MolnupiravirIt has been registered as Hong Kong pharmaceutical products in accordance with the regulations of the pharmaceutical industry and toxic drugs (Chapter 138A).At present, the only two models have been approved by the Hong Kong Pharmacy and Poison Administration (Administration) for the treatment of crown diseases.

The Hong Kong Department of Health said that these two crown disease oral drugs can only be supplied to public and private medical institutions and doctors, and patients can only obtain prescriptions about drugs by registered doctors.Purchasing and selling oral drugs to citizens.Considering that when using the two registered crown disease oral drugs, the Administration needs to pay attention to whether the patient's application is applicable, as well as related taboos and possible side effects.

The Hong Kong Department of Health reiterated that anyone illegally managed and sold without a doctor's prescription, and illegal management and sales of unregistered products are illegal.The fine HK $ 100,000 (about S $ 17,200) and imprisonment were sentenced to two years.

According to the official website of the China State Drug Administration, Phaxlovid's Paxlovid was approved to be listed in China in February 2022.On December 14, Pfizer announced that he signed with China Medicine for 2023 Coronatte Virus Treatment Drug Nametvil Film/Litonovid Package Package (PAXLOVID) import distribution agreement. Chinese medicine will be responsible for Paxlovid during the agreement period in mainland ChinaThe development of market imports and distribution business.

And another Merhadon New Guan Oral medication was just announced on Friday (December 30) that it was approved in mainland China.